A phase I study of BMS-247550 [ixabepilone] (NSC 710428) given weekly x 3 every 4 weeks in patients with advanced malignancies
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2013
At a glance
- Drugs Ixabepilone (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 18 Sep 2005 New trial record.